BRCA2 and Fanconi anemia: As a member of the Fanconi anemia pathway, BRCA2 (FANCD1)-deficient cells are extremely sensitive to crosslinking agents and platinum drugs such as cisplatin or mitomycin C (MMC)2; therefore, we next performed clonogenic survival assays to assess the sensitivity of cells bearing NTD variants and the CTD variant to increasing concentrations of MMC.